Our group is focused on developing chimeric antigen receptor T cells for haematological malignancies with a particular interest in gene edited allogeneic CAR T cells. We are exploring the mechanisms of resistance of myeloma, lymphoma and CLL towards CAR T cells using multi-OMICS assays and by evaluating primary samples from patients treated with CD19 and BCMA targeted CAR T cells.